Turing, a small drugmaker, ignited a fierce debate over drugs that treat rare diseases when it hiked the price of a medicine that’s been around for decades by 5,000%. Now the company is reversing course.
Turing, a small drugmaker, ignited a fierce debate over drugs that treat rare diseases when it hiked the price of a medicine that’s been around for decades by 5,000%. Now the company is reversing course.